On Thursday shares of Opko Health, Inc. (NYSE:OPK) closed at $16.68. Company’s sales growth for last 5 years was 83.30% and EPS growth for next 5 years is recorded as 7.50%. Opko Health, Inc. (NYSE:OPK) on May 11, 2015, declared operating and financial results for its first quarter ended March 31, 2015. Consolidated revenues increased to $30.1 million during the three months ended March 31, 2015 from $22.3 million in the comparable period of 2014.
Trevena, Inc. (NASDAQ:TRVN) in last trading activity moved up 2.52% to close at $6.92. Company weekly performance is 10.90% while its quarterly performance stands at 31.31%. Trevena, Inc. (NASDAQ:TRVN) is -15.20% away from its 52 week high. Trevena, Inc. (NASDAQ:TRVN) announced that data highlighting its preclinical TRV250 program will be presented in an oral presentation at the International Headache Congress being held in Valencia, Spain, May 14-17, 2015.
On last trading day MV Oil Trust (NYSE:MVO) decreased -2.25% to close at $11.73. Its volatility for the week is 3.55% while volatility for the month is 3.47%. MVO’s sales growth for past 5 years was 16.00% and its EPS growth for past 5 years was 16.90%. MV Oil Trust (NYSE:MVO) monthly performance is -8.86%. Analysts at Zacks
upgraded shares of MV Oil Trust (NYSE:MVO) from an “underperform” rating to a “neutral” rating
On last trading day Pandora Media Inc (NYSE:P) moved down -0.42% to close at $18.81. Its volatility for the week is 3.29% while volatility for the month is 4.09%. P’s sales growth for past 5 years was 75.60% and its EPS growth for past 5 years was 0.00%. Pandora Media Inc (NYSE:P) monthly performance is 8.41%. Pandora Media Inc (NYSE:P) said it will appeal a rate court ruling that could force the company to pay higher royalties to Broadcast Music Inc (BMI) for music licenses.
On last trading day BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) moved up 2.43% to close at $10.55. Its volatility for the week is 5.59% while volatility for the month is 4.94%. BCRX’s sales growth for past 5 years was -28.90% and its EPS growth for past 5 years was -14.20%. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) monthly performance is 7.43%. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) said Wednesday it began testing an experimental treatment on human volunteers for a rare and potentially fatal genetic disorder called hereditary angioedema.